Eyenovia, Inc. Announces Proposed Public Offering of Common Stock
August 18 2020 - 4:03PM
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic
biopharmaceutical company developing a pipeline of microdose array
print (MAP™) therapeutics, today announced that it intends to offer
and sell shares of its common stock in an underwritten public
offering. In connection with this offering, Eyenovia expects to
grant the underwriter a 30-day option to purchase up to an
additional 15% of the shares of common stock to be sold in the
offering. The offering is subject to market and other conditions,
and there can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms of the
offering. All of the shares in the proposed offering are to be sold
by Eyenovia.
Eyenovia intends to use the net proceeds from the public
offering, together with existing funds, to fund the continued
clinical development of its product candidates, initial
commercialization activities for MicroStat, and for working capital
and general corporate purposes.
William Blair & Company, L.L.C. is acting as sole
book-running manager for the offering.
The offering is being made pursuant to a shelf registration
statement on Form S-3 (File No. 333-229365) that was declared
effective by the Securities and Exchange Commission (the “SEC”) on
February 12, 2019. A preliminary prospectus supplement related to
the offering will be filed with the SEC and will be available on
the SEC’s website, located at www.sec.gov. Copies of the
preliminary prospectus supplement and the accompanying prospectus
relating to the offering, when available, may also be obtained from
William Blair & Company, L.L.C., Attention: Prospectus
Department, 150 North Riverside Plaza, Chicago, IL 60606, or by
calling (800) 621-0687, or emailing prospectus@williamblair.com.
The final terms of the offering will be disclosed in a final
prospectus supplement to be filed with the SEC.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities nor shall there be
any offer or sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction. Any offer, if at all, will be made only
by means of a prospectus supplement and accompanying prospectus,
which are a part of the effective registration statement.
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic
biopharmaceutical company developing a pipeline of microdose array
print (MAP™) therapeutics. Eyenovia’s pipeline is currently focused
on the late-stage development of microdosed medications for
presbyopia, myopia progression and mydriasis. For more Information,
please visit www.eyenovia.com.
Forward-Looking Statements
Except for historical information, all of the statements,
expectations, and assumptions contained in this press release are
forward-looking statements. Forward-looking statements
include, but are not limited to, statements that express our
intentions, beliefs, expectations, strategies, predictions or any
other statements relating to our future activities or other future
events or conditions. These statements are based on current
expectations, estimates and projections about our business based,
in part, on assumptions made by management. These statements are
not guarantees of future performance and involve risks,
uncertainties and assumptions that are difficult to predict.
Therefore, actual outcomes and results may, and are likely to,
differ materially from what is expressed or forecasted in the
forward-looking statements due to numerous factors discussed from
time to time in documents which we file with the SEC. In addition,
such statements could be affected by risks and uncertainties
related to, among other things, market conditions, the satisfaction
of customary closing conditions for the proposed offering, the
Company’s expected use of the net proceeds from the public
offering, its need to raise additional capital even after this
financing, and other risks and uncertainties described in
Eyenovia’s filings with the SEC. Any forward-looking statements
speak only as of the date on which they are made, and except as may
be required under applicable securities laws, Eyenovia does not
undertake any obligation to update any forward-looking
statements.
Company Contact:Eyenovia, Inc.John
GandolfoChief Financial Officerjgandolfo@eyenoviabio.com
Investor Contact:The Ruth GroupAlexander
LoboPhone: 646-536-7037alobo@theruthgroup.com
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Apr 2023 to Apr 2024